Biocompatibility at Risk: The Hidden Threat of Di (2-ethylhexyl) Phthalate (DEHP) in Pediatric and Oncology Infusion Systems | ||||
| Egyptian Journal of Health Care | ||||
| Volume 16, Issue 3, September 2025, Page 63-90 PDF (567.11 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhc.2025.443539 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Selwan Hamza Elgazzar; Yasmin Moustafas Ayoub; Eman Ramadan | ||||
| Nursing Education Administration | ||||
| Abstract | ||||
| Background: Di (2-ethylhexyl) phthalate (DEHP), a common plasticizer in polyvinyl chloride (PVC)medical devices, has been linked to endocrine disruption, hepatotoxicity, and reproductive harm. Despite global regulatory alerts, DEHP-containing infusion systems—including IV sets and blood bags—remain in use, particularly in pediatric, oncology, and transfusion-dependent populations. Aim:. To assess DEHP-related risks and propose a nursing-led framework for safer, biocompatible infusion practices. Design: A narrative-based theoretical analysis integrating scientific literature, toxicological data, international regulatory positions, and economic considerations. Setting: review was conducted within a multidisciplinary academic framework, guided by international patient safety standards (e.g., JCI, CBAHI, and Magnet’s NK3). Tool of Data Collection: Structured comparative tables were used to synthesize findings related to toxicological markers, pharmacological interactions, risk stratification, regulatory gaps, labeling attributes, and cost-effectiveness. Results: DEHP exposure correlated with elevated FSH/LH, pubertal delay, liver enzyme abnormalities, and reduced fertility. Drug adsorption and compromised chemotherapy efficacy were observed with DEHP-lined IV sets. Regulatory reviews revealed fragmented global policies and weak substitution enforcement. DEHP-free alternatives (e.g., EVA, TOTM) demonstrated better safety profiles and were cost-justified in high-risk groups. A nurse-driven screening checklist was developed. A nurse-driven screening checklist was developed to support clinical decision-making. Conclusion: DEHP use in infusion systems represents a preventable hazard in vulnerable populations. Biocompatible alternatives offer superior clinical outcomes and should replace DEHP-containing devices in critical care settings. Recommendations: Healthcare institutions must adopt DEHP-specific labeling, enforce substitution policies, and implement mandatory biocompatibility training. Accrediting bodies such as JCI and CBAHI should revise patient safety metrics to include material-related risks, while procurement models must shift toward value-based, risk-informed approaches. | ||||
| Keywords | ||||
| DEHP; PVC medical devices; infusion systems; biocompatibility; pediatric oncology; NICU; chemotherapy efficacy; nursing-led risk assessment; regulatory policy; patientsafety | ||||
|
Statistics Article View: 137 PDF Download: 131 |
||||
